From venture capital to cancer biotech COO: how Jeremy turned personal loss into purpose
Singapore Economic Development Board (first published by the Singapore Global Network)
What was covered
A profile of why Jeremy left venture capital to become COO of Lucence. It traces his path from a teenage ambition to be a vaccine researcher, through consulting, founding companies and VC, to a role fighting the disease that took a loved one, and explains Lucence’s blood-based cancer tests.
Key points
- He once wanted to be a vaccine researcher; losing a loved one to cancer in junior college pushed him toward economics and business at UC Berkeley
- Career arc covers social impact consulting, Bain, co-founding Conjunct Consulting, a Harvard MBA and CozyKin
- At Monk’s Hill Ventures he grew a weekend podcast into BRAVE Southeast Asia, a major regional tech podcast
- He joined Lucence after meeting founder Dr Min-Han Tan, drawn by the chance to improve cancer diagnostics at scale
- Lucence uses next-generation sequencing for liquid biopsies, including a treatment-guiding test and a screening range of up to 50 cancer types
- Commercial milestones cited: US Medicare coverage for its test and a 2025 collaboration with Mayo Clinic Laboratories
- Central theme: innovation only matters if people can access it, so the goal is making screening as routine and affordable as a health check
- Lucence credits Enterprise Singapore, SGInnovate and Heliconia for helping it scale
Summary written from the full source page.